Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Rivastigmine is a cholinesterase inhibitor which improves cognitive function and is currently being used in patients with mild to moderate Parkinson’s and Alzheimer’s dementia. This drug can be given orally or topically, as transdermal patch. The latter form is currently used for most excellent compliance and few side effects. The most common cutaneous side effects are irritative dermatitis. We report the second case of active sensitization by the rivastigmine-patch in a patient suffering from Alzheimer’s dementia. 1
Transdermal therapeutic systems (TTS) have become a popular method of drug delivery because they all...
Abstract Objectives: To conduct a preliminary assessment of the effects of the oral and transdermal...
Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Ga...
Rivastigmine is a cholinesterase inhibitor which improves cognitive function and is currently being ...
Rivastigmine is a well-known dual acting acetylcholinesterase and butyrylcholinesterase inhibitor, w...
rivastigmine patch is widely used as a cognitive enhancer in Alzheimer’s-type dementia. There are ve...
Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Ga...
Abstract There is not much published literature on the use of rivastigmine patch in a "routine" clin...
Hypertrichosis is the excessive hair growth in any area of the skin surface. Acquired localized hype...
Background and Purpose The one-day rivastigmine patch is reportedly well tolerated and has minimal ...
The dual cholinesterase inhibitor rivastigmine is approved in capsule form in many countries for the...
Cholinesterase inhibitors have all been available in oral formulations, but a rivastigmine transderm...
SummaryRivastigmine is a well-known dual acting acetylcholinesterase and butyrylcholinesterase inhib...
A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routin...
Takashi Osada,1 Norio Watanabe,1 Naomitsu Asano,2 Yuzo Adachi,2 Keiko Yamamura1 1Clinical Pharmacy,...
Transdermal therapeutic systems (TTS) have become a popular method of drug delivery because they all...
Abstract Objectives: To conduct a preliminary assessment of the effects of the oral and transdermal...
Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Ga...
Rivastigmine is a cholinesterase inhibitor which improves cognitive function and is currently being ...
Rivastigmine is a well-known dual acting acetylcholinesterase and butyrylcholinesterase inhibitor, w...
rivastigmine patch is widely used as a cognitive enhancer in Alzheimer’s-type dementia. There are ve...
Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Ga...
Abstract There is not much published literature on the use of rivastigmine patch in a "routine" clin...
Hypertrichosis is the excessive hair growth in any area of the skin surface. Acquired localized hype...
Background and Purpose The one-day rivastigmine patch is reportedly well tolerated and has minimal ...
The dual cholinesterase inhibitor rivastigmine is approved in capsule form in many countries for the...
Cholinesterase inhibitors have all been available in oral formulations, but a rivastigmine transderm...
SummaryRivastigmine is a well-known dual acting acetylcholinesterase and butyrylcholinesterase inhib...
A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routin...
Takashi Osada,1 Norio Watanabe,1 Naomitsu Asano,2 Yuzo Adachi,2 Keiko Yamamura1 1Clinical Pharmacy,...
Transdermal therapeutic systems (TTS) have become a popular method of drug delivery because they all...
Abstract Objectives: To conduct a preliminary assessment of the effects of the oral and transdermal...
Cholinesterase inhibitors constitute one of the mainstays of treatment of Alzheimer disease (AD). Ga...